FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891898075> ?p ?o ?g. }

• W2891898075 endingPage "38" @default.
• W2891898075 startingPage "27" @default.
• W2891898075 abstract "Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after solid organ and hematopoietic stem cell transplantation, associated with significant morbidity and mortality. In this systematic review we evaluated the clinical performance of advanced imaging modalities at diagnosis and treatment response evaluation of PTLD patients after solid organ and hematopoietic stem cell transplantation.We have carried out a literature search until December 15, 2017 using PubMed/Medline, Embase, Web of Science and Cochrane Library databases concerning the performance of computed tomography (CT), magnetic resonance imaging (MRI) and 18F-flurodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) at diagnosis or treatment response evaluation of PTLD patients.A total of 11 studies were included comprising 368 patients, from which FDG-PET(/CT) was the primary imaging modality investigated. The methodological quality according to QUADAS-2 of the reviewed studies was moderate-poor. Subgroup analysis of imaging results for detection and staging in patients with PTLD indicated that FDG-PET/(CT) identified additional lesions not detected by CT and/or MRI in 27.8%, (95% confidence interval [95%CI]) 17.0%-42.0% (I2 = 51.1%), from which extra-nodal sites in 23.6% (95%CI: 7.9%-52.4%) (I2 = 76.6%). False negative results occurred in 11.5% (95%CI: 4.9%-24.5%) (I2 = 73.4%), predominantly in physiological high background activity regions and in early PTLD lesions. False positive results occurred in 4.8% (95%CI: 2.6%-8.6%) (I2 = 0%) predominantly due to inflammatory conditions. Subgroup analysis of imaging results at treatment response evaluation indicated that FDG-PET(/CT) findings altered or guided treatment in 29.0% (95%CI: 14.0%-50.5%) (I2 = 40.1%). False positive results during treatment response evaluation were reported in 20.0% (95%CI: 10.7%-34.2%) (I2 = 0%), predominantly due to inflammatory conditions.FDG-PET(/CT) is currently the most frequently investigated imaging modality in PTLD patients. Available studies report promising results in detection, staging and therapy evaluation but suffer from methodological shortcomings. Concerns remain with regard to occurrence of false negatives due to physiological high background activity and early PTLD lesions as well as false positives due to inflammatory conditions." @default.
• W2891898075 created "2018-09-27" @default.
• W2891898075 creator A5002550691 @default.
• W2891898075 creator A5003581995 @default.
• W2891898075 creator A5010863711 @default.
• W2891898075 creator A5014923760 @default.
• W2891898075 creator A5019778216 @default.
• W2891898075 creator A5023678666 @default.
• W2891898075 creator A5024047541 @default.
• W2891898075 creator A5030515123 @default.
• W2891898075 creator A5033063736 @default.
• W2891898075 creator A5033586033 @default.
• W2891898075 creator A5043125083 @default.
• W2891898075 creator A5070411055 @default.
• W2891898075 date "2018-12-01" @default.
• W2891898075 modified "2023-10-13" @default.
• W2891898075 title "Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis" @default.
• W2891898075 cites W116758776 @default.
• W2891898075 cites W1507619039 @default.
• W2891898075 cites W1696276358 @default.
• W2891898075 cites W1844176187 @default.
• W2891898075 cites W1925602349 @default.
• W2891898075 cites W1963899515 @default.
• W2891898075 cites W1965069903 @default.
• W2891898075 cites W1967587135 @default.
• W2891898075 cites W1989488484 @default.
• W2891898075 cites W1990145820 @default.
• W2891898075 cites W1997276706 @default.
• W2891898075 cites W1999792678 @default.
• W2891898075 cites W2000957415 @default.
• W2891898075 cites W2007872832 @default.
• W2891898075 cites W2013078073 @default.
• W2891898075 cites W2022174888 @default.
• W2891898075 cites W2023109076 @default.
• W2891898075 cites W2023275887 @default.
• W2891898075 cites W2029710808 @default.
• W2891898075 cites W2035328957 @default.
• W2891898075 cites W2036030274 @default.
• W2891898075 cites W2037764680 @default.
• W2891898075 cites W2048288179 @default.
• W2891898075 cites W2050748027 @default.
• W2891898075 cites W2051354228 @default.
• W2891898075 cites W2054279695 @default.
• W2891898075 cites W2055375238 @default.
• W2891898075 cites W2056913911 @default.
• W2891898075 cites W2060390829 @default.
• W2891898075 cites W2061446569 @default.
• W2891898075 cites W2063193596 @default.
• W2891898075 cites W2063365882 @default.
• W2891898075 cites W2077941010 @default.
• W2891898075 cites W2083061869 @default.
• W2891898075 cites W2086380649 @default.
• W2891898075 cites W2102222690 @default.
• W2891898075 cites W2107638293 @default.
• W2891898075 cites W2116323676 @default.
• W2891898075 cites W2120617891 @default.
• W2891898075 cites W2125435699 @default.
• W2891898075 cites W2126297385 @default.
• W2891898075 cites W2131900456 @default.
• W2891898075 cites W2135455909 @default.
• W2891898075 cites W2144427011 @default.
• W2891898075 cites W2155767198 @default.
• W2891898075 cites W2157666918 @default.
• W2891898075 cites W2161811075 @default.
• W2891898075 cites W2170308172 @default.
• W2891898075 cites W2223411236 @default.
• W2891898075 cites W2225072291 @default.
• W2891898075 cites W2272544270 @default.
• W2891898075 cites W2281543691 @default.
• W2891898075 cites W2291210741 @default.
• W2891898075 cites W2496657814 @default.
• W2891898075 cites W2507439586 @default.
• W2891898075 cites W2516029706 @default.
• W2891898075 cites W2550105382 @default.
• W2891898075 cites W2749512963 @default.
• W2891898075 cites W2769398810 @default.
• W2891898075 cites W2786571997 @default.
• W2891898075 doi "https://doi.org/10.1016/j.critrevonc.2018.09.007" @default.
• W2891898075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30447925" @default.
• W2891898075 hasPublicationYear "2018" @default.
• W2891898075 type Work @default.
• W2891898075 sameAs 2891898075 @default.
• W2891898075 citedByCount "25" @default.
• W2891898075 countsByYear W28918980752019 @default.
• W2891898075 countsByYear W28918980752020 @default.
• W2891898075 countsByYear W28918980752021 @default.
• W2891898075 countsByYear W28918980752022 @default.
• W2891898075 countsByYear W28918980752023 @default.
• W2891898075 crossrefType "journal-article" @default.
• W2891898075 hasAuthorship W2891898075A5002550691 @default.
• W2891898075 hasAuthorship W2891898075A5003581995 @default.
• W2891898075 hasAuthorship W2891898075A5010863711 @default.
• W2891898075 hasAuthorship W2891898075A5014923760 @default.
• W2891898075 hasAuthorship W2891898075A5019778216 @default.
• W2891898075 hasAuthorship W2891898075A5023678666 @default.
• W2891898075 hasAuthorship W2891898075A5024047541 @default.
• W2891898075 hasAuthorship W2891898075A5030515123 @default.
• W2891898075 hasAuthorship W2891898075A5033063736 @default.

• next